Gerburg Wulf

20PUBLICATIONS
142CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMedical infection agents (incl. prions)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 30, 2026
A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer.

|Feb 06, 2026
MicroRNA spatial profiling for assessing drug efficacy in BRCA1 -related triple-negative breast tumors.

Omar N Mohd, Lin Wang, Brian R Sardella

|Jan 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Nadine M Tung, Mark E Robson, Tianyu Li

|Jan 06, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Mrinal Gounder, Melissa Johnson, Rebecca S Heist

|May 08, 2024
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.

Zhanfang Guo, Jingqin Luo, R Jay Mashl

|Apr 15, 2024
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry.

Shizhong Ke, Fabin Dang, Lin Wang

Pageof 4

Frequent Collaborators

4 joint publications

Geoffrey I Shapiro

4 joint publications

Nadine M Tung

4 joint publications

Jennifer L Guerriero

3 joint publications

Felipe Batalini